UNSPSC 51384508: Flurbiprofen

This classification denotes a cyclooxygenase inhibitor and carbonic anhydrase inhibitor with the molecular formula C15H13FO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5GRO578KLP, chemically known as 4-biphenylacetic acid, 2-fluoro-alpha-methyl- but generally known as flurbiprofen, which bears US NIH Compound Identifier 3394. European Medicines Agency schedules Flurbiprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07745MIG.

UNSPSC 51384508 Flurbiprofen is a Commodity code, but the recent state and local opportunities posted under it show minimal direct alignment with flurbiprofen procurement specifically. Instead, the opportunities reflect broader pharmaceutical and drug-related product sourcing: naloxone and drug deactivation systems for emergency response, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing. The code appears to capture pharmaceutical procurement activity more generally rather than flurbiprofen as a discrete product line. State and local governments buying under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that serve state agencies and local government facilities across multiple jurisdictions.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, due July 26, 2023). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. The MMCAP opportunity emphasizes compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, pricing transparency through authorized wholesalers, and multi-award potential based on therapeutic considerations and product availability.